Literature DB >> 7443111

Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.

A L Hartikainen-Sorri, A Kauppila, R Tuimala.   

Abstract

There are indications that prophylactic administration of 17 alpha-hydroxyprogesterone caproate (17 alpha-OHP-C) could be beneficial in the treatment of women at risk for preterm delivery. Since twin pregnancy is commonly associated with prematurity, 77 women with twin pregnancy were treated during the last trimester until the 37th gestational week with weekly injections of either 17 alpha-OHP-C or a placebo, following double-blind principles. The gestational length and birth weight and the outcome of the neonates were similar in both groups. The administration of 17 alpha-OHP-C thus seems ineffective in the prevention of prematurity risks associated with twin pregnancy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7443111

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

Review 1.  Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data.

Authors:  Roberto Romero; Kypros Nicolaides; Agustin Conde-Agudelo; Ann Tabor; John M O'Brien; Elcin Cetingoz; Eduardo Da Fonseca; George W Creasy; Katharina Klein; Line Rode; Priya Soma-Pillay; Shalini Fusey; Cetin Cam; Zarko Alfirevic; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2011-12-11       Impact factor: 8.661

Review 2.  Progesterone treatment to prevent preterm birth.

Authors:  Paul J Meis; Alicia Aleman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.

Authors:  Barbara J Attardi; Anthony Zeleznik; Hyagriv Simhan; Jye Ping Chiao; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

Review 4.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 5.  Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.

Authors:  Jodie M Dodd; Rosalie M Grivell; Cecelia M OBrien; Therese Dowswell; Andrea R Deussen
Journal:  Cochrane Database Syst Rev       Date:  2017-10-31

6.  Management of pregnancies with cervical shortening: a very short cervix is a very big problem.

Authors:  Hee Joong Lee; Tae Chul Park; Errol R Norwitz
Journal:  Rev Obstet Gynecol       Date:  2009

7.  Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.

Authors:  Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin
Journal:  Am J Obstet Gynecol       Date:  2013-10-07       Impact factor: 8.661

8.  The role of progesterone in prevention of preterm birth.

Authors:  Jodie M Dodd; Caroline A Crowther
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

10.  Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial.

Authors:  Jodie M Dodd; Caroline A Crowther; Andrew J McPhee; Vicki Flenady; Jeffrey S Robinson
Journal:  BMC Pregnancy Childbirth       Date:  2009-02-24       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.